Becton, Dickinson and Company - US Medtechwert
eröffnet am 10.09.08 13:38:39 von
neuester Beitrag 28.11.23 05:19:19 von
neuester Beitrag 28.11.23 05:19:19 von
Beiträge: 44
ID: 1.144.119
ID: 1.144.119
Aufrufe heute: 0
Gesamt: 7.669
Gesamt: 7.669
Aktive User: 0
ISIN: US0758871091 · WKN: 857675 · Symbol: BDX
231,55
USD
+0,46 %
+1,07 USD
Letzter Kurs 02:04:00 NYSE
Neuigkeiten
Werte aus der Branche Gesundheitswesen
Wertpapier | Kurs | Perf. % |
---|---|---|
4,9700 | +324,79 | |
1,7800 | +36,92 | |
19,30 | +26,30 | |
13,760 | +22,86 | |
0,6577 | +19,36 |
Wertpapier | Kurs | Perf. % |
---|---|---|
0,5925 | -15,36 | |
0,6835 | -20,53 | |
3,9200 | -23,14 | |
0,6100 | -51,20 | |
1,8819 | -55,93 |
Beitrag zu dieser Diskussion schreiben
Entflechtung / Spin off
Hallo ist da jemand !Diskussion über Becton, Dickinson ist ziemlich dürftig.
Habe in meinen Depot Embecta Corp. Aktien eingebucht bekommen.
Leider keine Diskussion darüber. Soll man die behalten oder nicht ?
Soll ein Isulin Spezialist sein.
Habe aufgerundet das heisst zugekauft.
In meinem Depot habe ich auch novo nordisk Aktien. Auch ein Insulin Spezialist.
Diese Papiere haben sich über die Jahre extrem gut entwickelt.
Gruss, und viel erfolg
Paul MacDonald discusses Becton Dickinson
https://www.bnnbloomberg.ca/video/paul-macdonald-discusses-b…
https://www.bnnbloomberg.ca/video/paul-macdonald-discusses-b…
Paul Harris discusses Becton Dickinson
https://www.bnnbloomberg.ca/video/paul-harris-discusses-bect…
https://www.bnnbloomberg.ca/video/paul-harris-discusses-bect…
Jennifer Radman discusses Becton Dickinson
https://www.bnnbloomberg.ca/video/jennifer-radman-discusses-…
https://www.bnnbloomberg.ca/video/jennifer-radman-discusses-…
Gordon Reid discusses Becton Dickinson
https://www.bnnbloomberg.ca/video/gordon-reid-discusses-bect…
https://www.bnnbloomberg.ca/video/gordon-reid-discusses-bect…
Hallo zusammen,
I'm back nach 12 jähren Pause an der Börse. Habe mich hier wieder freischalten lassen, werde aber nicht so aktiv sein wie früher...
Habe vor 2 Wochen eine erste Position gekauft.
Wer ist noch da, der mich kennt?
Gruß an alle!
I'm back nach 12 jähren Pause an der Börse. Habe mich hier wieder freischalten lassen, werde aber nicht so aktiv sein wie früher...
Habe vor 2 Wochen eine erste Position gekauft.
Wer ist noch da, der mich kennt?
Gruß an alle!
Antwort auf Beitrag Nr.: 57.688.821 von 1435905 am 03.05.18 18:49:5208/02/2018 | 07:26am EDT
By Nishant Mohan
Becton, Dickinson and Co. (BDX) posted its first profit for the year on Thursday, beating analyst expectations for per-share earnings in the third quarter.
The medical technology company reported third-quarter net income of $556 million, compared with a loss of $165 million a year ago.
Adjusting for the costs of its acquisitions of C. R. Bard Inc. and CareFusion Corp. and other charges, the company reported per-share earnings of $2.91 compared with $2.46 a year ago and beating a $2.86 consensus estimate from analysts polled by FactSet.
The company's revenue rose 41% to $4.28 billion.
The company narrowed its guidance for the year, now expecting year-over-year growth of 31.5% compared with previous guidance predicting 31% to 31.5%
Shares of the company are up 16.8% to $250 a share so far this year.
Write to Nishant Mohan at nishant.mohan@wsj.com
http://www.4-traders.com/BECTON-DICKINSON-AND-COM-11801/news…
By Nishant Mohan
Becton, Dickinson and Co. (BDX) posted its first profit for the year on Thursday, beating analyst expectations for per-share earnings in the third quarter.
The medical technology company reported third-quarter net income of $556 million, compared with a loss of $165 million a year ago.
Adjusting for the costs of its acquisitions of C. R. Bard Inc. and CareFusion Corp. and other charges, the company reported per-share earnings of $2.91 compared with $2.46 a year ago and beating a $2.86 consensus estimate from analysts polled by FactSet.
The company's revenue rose 41% to $4.28 billion.
The company narrowed its guidance for the year, now expecting year-over-year growth of 31.5% compared with previous guidance predicting 31% to 31.5%
Shares of the company are up 16.8% to $250 a share so far this year.
Write to Nishant Mohan at nishant.mohan@wsj.com
http://www.4-traders.com/BECTON-DICKINSON-AND-COM-11801/news…
Antwort auf Beitrag Nr.: 57.688.746 von 1435905 am 03.05.18 18:45:04Die Zahlen waren gut, der Ausblick wurde leicht angehoben.
Der Kurs ist heute in ein mittleres rot getaucht (z.Z. 189€)
Vielleicht hatte der ein oder andere auf mehr spekuliert oder es sind schlicht Gewinnmitnahmen.
Der Kurs ist heute in ein mittleres rot getaucht (z.Z. 189€)
Vielleicht hatte der ein oder andere auf mehr spekuliert oder es sind schlicht Gewinnmitnahmen.
BD Raises FY18 Guidance
Becton, Dickinson and Company (BDX) increased its fiscal 2018 adjusted earnings per share guidance to be between $10.90 and $11.05 due to an increase in the estimated benefit from foreign currency. This represents growth of approximately 15.0 to 16.5 percent over fiscal 2017 adjusted diluted earnings per share, and is an increase from previous guidance of $10.85 to $11.00 which represented growth of approximately 15.0 to 16.0 percent. On a currency-neutral basis, the company continues to expect full fiscal year adjusted earnings per share growth of approximately 12.0 percent.The company now expects fiscal 2018 revenues to increase approximately 31.0 to 31.5 percent on a reported basis. This is an improvement from previously issued guidance of 30.0 to 31.0 percent growth. On a comparable, currency-neutral basis, the company raised its revenue guidance to 5.0 to 5.5 percent growth, which is the high end of its previous guidance range.
Second-quarter adjusted earnings per share were $2.65, compared with $2.30 in the prior-year period. This represents an increase in adjusted earnings per share of 15.2 percent, or 7.8 percent on a currency-neutral basis. Revenues of $4.222 billion, represents an increase of 42.2 percent from the prior-year period, which is primarily due to the acquisition of C. R. Bard. On a comparable, currency-neutral basis that includes the revenues of C.R. Bard in the current and prior year, revenues increased 5.7 percent over the prior-year period.
Quelle: dpa-AFX vom 03.05.2018
Becton, Dickinson and Company - US Medtechwert